Pasithea Therapeutics Warrants
KTTAW
KTTAW was delisted on the 15th of September, 2026.
0 hedge funds and large institutions have $0 invested in Pasithea Therapeutics Warrants in 2026 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 6 closing their positions.
100% less funds holding
Funds holding: 6 → 0 (-6)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $3.18K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kepos Capital
New York
|
-$2K |
| 2 |
Two Sigma Securities
New York
|
-$397 |
| 3 |
Armistice Capital
New York
|
-$345 |
| 4 |
Marex Group
London,
|
-$223 |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$216 |
KTTAW Hedge Fund Activity: Q3 2026 in Review
0 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q3 2026, worth a combined $0 — down 100% from $3.18K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KTTAW and 0 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Kepos Capital, exiting entirely with an estimated $2K sold.
- 0 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q3 2026, down from 6 in Q2 2026.
- Funds reported $0 of Pasithea Therapeutics Warrants stock for Q3 2026, down 100% quarter-over-quarter.
- 0 funds opened new Pasithea Therapeutics Warrants positions in Q3 2026 and 6 closed out, a net change of -6 holders.
- The largest Pasithea Therapeutics Warrants seller in Q3 2026 was Kepos Capital, an estimated $2K sold.
Based on aggregated 13F filings for Q3 2026.